Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.21
- Piotroski Score 4.00
- Grade Buy
- Symbol (VYGR)
- Company Voyager Therapeutics, Inc.
- Price $5.85
- Changes Percentage (0%)
- Change -$0
- Day Low $5.71
- Day High $5.86
- Year High $11.72
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $16.00
- High Stock Price Target $18.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.17
- Trailing P/E Ratio -49.53
- Forward P/E Ratio -49.53
- P/E Growth -49.53
- Net Income $132.33 M
Income Statement
Quarterly
Annual
Latest News of VYGR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Voyager Therapeutics reported strong quarterly results with revenue exceeding expectations by 211%. Analysts forecast a 65% decline in revenue for 2024 but an improvement in loss per share. The consen...
By Yahoo! Finance | 1 month ago -
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is definitely on the radar of institutional investors who own 49% of the company
Ownership research and analyst forecasts data provide insight into stock opportunities. Institutions own 49% of Voyager Therapeutics, indicating strong potential. Hedge funds and Neurocrine Bioscience...
By Yahoo! Finance | 2 months ago
